| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 南京健友于2017年7月19日在上交所A股上市，公司拥有全球领先的隔离器生产线、高端无菌注射剂生产技术，以及通过了中国、美国、欧洲、日本、巴西等多地区认证的全球化质量体系。拥有世界级生产研发速度、全球化的质量意识、扎根美国的销售能力，同时可提供以中美市场为核心、覆盖全球的注射剂CDMO服务，公司新成立生物创新药事业部，聚合全球创新人才，推动公司走向创新型、国际化，建设世界一流的生物药公司。 公司主营药品原料、制剂的研发、生产和销售，产品涵盖肝素原料药（包括标准肝素原料药和低分子肝素原料药）、肝素制剂（包括标准肝素制剂和低分子肝素制剂）、非肝素制剂（抗肿瘤制剂、抗感染制剂等）。此外，依托先进的工艺研发能力和生产设备，公司为全球及国内知名药企提供制剂端一站式的CDMO服务。 | ||||||||||||||||||||||||
| Main Business | 药品原料、制剂的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 唐咏群 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 黄锡伟 | ||||||||||||||||||||||||
| Solicitors | 江苏世纪同仁律师事务所 | ||||||||||||||||||||||||
| Auditors | 天衡会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 025-86990789 | ||||||||||||||||||||||||
| Fax No | 025-86990710 | ||||||||||||||||||||||||
| Website | www.nkf-pharma.com | ||||||||||||||||||||||||
| Nkf-pharma@nkf-pharma.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 19/07/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.120 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.100 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.558 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 23.217B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |